First published July 1, 2013 - More info
The BRAF mutant, BRAFV600E, is expressed in nearly half of melanomas, and oral BRAF inhibitors induce substantial tumor regression in patients with
Deborah A. Knight, Shin Foong Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok, Ashley Cass, Nicole M. Haynes, Kathryn Kinross, Hideo Yagita, Richard C. Koya, Thomas G. Graeber, Antoni Ribas, Grant A. McArthur, Mark J. Smyth
Original citation: J. Clin. Invest. 2013;123(3):1371–1381. doi:10.1172/JCI66236.
Citation for this erratum: J. Clin. Invest. 2013;123(7):3182. doi:10.1172/JCI70645.
During preparation of the manuscript, Figure 9 was labeled incorrectly. The correct figure is below.
The JCI regrets the error.